Corsee D. Sanders

Corsee D. Sanders, Ph.D., was most recently the Strategic Advisor to the Celgene Office of the Chief Medical Officer. She was on the Executive Committee of Juno Therapeutics from January 2017 up to its acquisition by Celgene in 2018, reporting to the CEO and accountable for Quantitative Sciences, Project Leadership, Development Operations, and CAR T Patient Operations. Prior to Juno, Dr. Sanders spent 7 years with Roche Pharmaceuticals in various roles, including Global Head of Biometrics, Global Head of Clinical Operations, and Global Head of Industry Collaborations. She was a member of the Late Stage Portfolio Committee, Co-chair of the Roche-Chugai Joint Portfolio Management Committee, and Vice-chair of the Board of Directors of TransCelerate Inc., on behalf of Roche. She spent 15 years with Genentech, Inc., prior to its acquisition by Roche, leading functions including Clinical and Nonclinical Biostatistics, Health Economics, Epidemiology, Real World Evidence, Business and Data Operations. Prior to that, she was a Biostatistics leader with Schering-Plough in NJ, and Centocor, Inc. in Malvern, PA. She started her career as a statistician with the Technical Board for Agricultural Credit, an arm of the Presidential Committee on Agricultural Credit in the Philippines. Dr. Sanders holds Bachelor and Master of Science degrees in statistics from the University of the Philippines and a Ph.D. in Statistics from the Wharton Doctoral Programs of the University of Pennsylvania. Dr. Sanders is a member of the Board of Trustees at Fred Hutchinson Cancer Research Center and a board director of Molecular Templates.